ASTRO applauds CMS decision to cover annual screening for high-risk lung cancer patients

The American Society for Radiation Oncology (ASTRO) commends the February 5, 2015, decision by the Centers for Medicare and Medicaid Services (CMS) to provide coverage for annual lung cancer screening via low-dose CT screening for those at highest-risk for lung cancer.

The final Decision Memo for Screening for Lung Cancer with Low Dose Computed Tomography (LDCT) (CAG-00439N) details that there is sufficient evidence to warrant annual lung cancer screening for patients most at-risk for developing lung cancer.

The Memo outlines the patient criteria for eligibility as follows: age, 55 to 77 years; no signs or symptoms of lung disease; a smoking history of at least 30 pack-years (1 pack-year = smoking one pack [20 cigarettes] per day for 1 year); and currently smoking or has quit smoking within the last 15 years.

"CMS has taken a bold step that can potentially reduce the lung cancer mortality of patients at highest risk for lung cancer by nearly 20%. We are grateful for the additional opportunities that annual screening provides us to save hundreds of thousands of lives from lung cancer," said ASTRO Chair Bruce G. Haffty, MD, FASTRO.

"This year in the United States, it is estimated that nearly 230,000 men and women will be diagnosed with lung cancer, and that there will be more than 160,000 deaths from lung cancer, more deaths than from breast, colon, and prostate cancers combined. This highly effective, annual screening is a critical and powerful tool that will enable us to diagnose patients earlier when treatments are most effective, and it will fortify our efforts to battle this destructive disease."

In addition to detailing the patient health status for annual screening, the final decision also enumerates specific facility criteria and requirements, and care steps prior to and following screening. Two valuable care steps include a shared-decision making/smoking cessation counseling session between the physician and patient prior to the first screening and access to smoking cessation sessions available to current smokers—vital services that encourage current smokers to stop smoking, which directly impacts their treatment outcome.

Distinct screening guidelines are also provided: administer CT dose index volume of 3 mGy or less for standard-sized patients (approximately 155 lb), with appropriate reductions for smaller patients and increases for larger patients; utilize a standardized lung nodule identification, classification, and reporting system; and collect and submit patient data to a CMS-approved registry for each LDCT screening test.

CMS' decision follows the United States Preventive Task Force (USPSTF's) determination that LDCT is a Grade B screen, based on a review of the results from four randomized clinical trials including the National Cancer Institute's National Lung Screening Trial, which found a 16% reduction in lung cancer mortality in more than 50,000 asymptomatic adults ages 55 to 75 years with at least a 30 pack-year history who received annual screening and thus, earlier treatment.

Loading links....
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs